Improving cancer dose-response characterization by using physiologically based pharmacokinetic modeling: An analysis of pooled data for acrylonitrile-induced brain tumors to assess cancer potency in the rat

被引:14
作者
Kirman, CR
Hays, SM
Kedderis, GL
Gargas, ML
Strother, DE
机构
[1] McLaren Hart ChemRisk, Cleveland, OH 44124 USA
[2] CIIT Ctr Hlth Res, Res Triangle Pk, NC USA
[3] BP Chem Inc, Warrensville Hts, OH USA
关键词
cancer potency; PBPK; acrylonitrile; dose response;
D O I
10.1111/0272-4332.00013
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Historically, U.S. regulators have derived cancer slope factors by using applied dose and tumor response data from a single key bioassay or by averaging the cancer slope factors of several key bioassays. Recent changes in U.S. Environmental Protection Agency (EPA) guidelines for cancer risk assessment have acknowledged the value of better use of mechanistic data and better dose-response characterization. However, agency guidelines may benefit from additional considerations presented in this paper. An exploratory study was conducted by using rat brain tumor data for acrylonitrile (AN) to investigate the use of physiologically based pharmacokinetic (PBPK) modeling along with pooling of dose-response data across routes of exposure as a means for improving carcinogen risk assessment methods. In this study, two contrasting assessments were conducted for AN-induced brain tumors in the rat on the basis of (1) the EPA's approach, the dose-response relationship was characterized by using administered dose/concentration for each of the key studies assessed individually; and (2) an analysis of the pooled data, the dose-response relationship was characterized by using PBPK-derived internal dose measures for a combined database of ten bioassays. The cancer potencies predicted for AN by the contrasting assessments are remarkably different (i.e., risk-specific doses differ by as much as two to four orders of magnitude), with the pooled data assessments yielding lower values. This result suggests that current carcinogen risk assessment practices overestimate AN cancer potency. This methodology should be equally applicable to other data-rich chemicals in identifying (1) a useful dose measure, (2) an appropriate dose-response model, (3) an acceptable point of departure, and (4) an appropriate method of extrapolation from the range of observation to the range of prediction when a chemical's mode of action remains uncertain.
引用
收藏
页码:135 / 151
页数:17
相关论文
共 28 条
[1]  
[Anonymous], FED REG
[2]  
[Anonymous], 1986, Federal Register
[3]   PRIMARY BRAIN-TUMORS IN FISCHER-344 RATS CHRONICALLY EXPOSED TO ACRYLONITRILE IN THEIR DRINKING-WATER [J].
BIGNER, DD ;
BIGNER, SH ;
BURGER, PC ;
SHELBURNE, JD ;
FRIEDMAN, HS .
FOOD AND CHEMICAL TOXICOLOGY, 1986, 24 (02) :129-137
[4]   DEVELOPMENT OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR CHLOROFORM [J].
CORLEY, RA ;
MENDRALA, AL ;
SMITH, FA ;
STAATS, DA ;
GARGAS, ML ;
CONOLLY, RB ;
ANDERSEN, ME ;
REITZ, RH .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1990, 103 (03) :512-527
[5]  
*EPA, 1996, PROP GUID CARC RISK
[6]  
*EPA, 1980, CARC ASS GROUPS CARC
[7]  
EPA (Environmental Protection Agency), 1997, HLTH EFF ASS SUMM TA
[8]  
*FDA, 1981, C NOV 24 1981 M CANC
[9]   Acrylonitrile: A reevaluation of the database to support an inhalation cancer risk assessment [J].
Felter, SP ;
Dollarhide, JS .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1997, 26 (03) :281-287
[10]   NEOPLASMS IN RATS INGESTING ACRYLONITRILE FOR 2 YEARS [J].
GALLAGHER, GT ;
MAULL, EA ;
KOVACS, K ;
SZABO, S .
JOURNAL OF THE AMERICAN COLLEGE OF TOXICOLOGY, 1988, 7 (05) :603-615